SCHEMBL24735183

SCHEMBL24735183

OCC1CN(c2ccc(I)cc2F)C1

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAP2K1 Q02750 4/20 0.34
MAP2K2 P36507 3/20 0.34
MAPT P10636 5/20 0.33
GAA P10253 2/20 0.33
HPGD P15428 4/20 0.33
ALDH1A1 P00352 4/20 0.33
TSHR P16473 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.32
RAB9A P51151 3/20 0.32
SYK P43405 2/20 0.32
NPC1 O15118 2/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
DPP4 P27487 1/20 0.31
DPP8 Q6V1X1 1/20 0.31
DPP9 Q86TI2 1/20 0.31
DPP7 Q9UHL4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24735234 0.88 SYK (0.39) MAPTGAAHPGDSMN1; SMN2SYK
SCHEMBL24735592 0.88 SYK (0.39) MAPTGAAHPGDSMN1; SMN2SYK
SCHEMBL24735337 0.88 SYK (0.39) MAPTGAAHPGDSMN1; SMN2SYK
SCHEMBL29890092 0.84 GAA (0.43) MAPTGAAHPGDALDH1A1TSHR
SCHEMBL22505545 0.84 GAA (0.43) MAPTGAAHPGDALDH1A1TSHR
SCHEMBL24735187 0.81 ALDH1A1 (0.49) MAPTGAAHPGDALDH1A1TSHR
SCHEMBL29106898 0.75 ALDH1A1 (0.57) MAPTGAAALDH1A1SMN1; SMN2MEN1
SCHEMBL24735181 0.74 ALDH1A1 (0.41) MAP2K1MAP2K2MAPTGAAHPGD
SCHEMBL21877146 0.72 LTA4H (0.40) MAPTSYK
SCHEMBL25714092 0.72 ALDH1A1 (0.56) MAPTGAAHPGDALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117042769-A Substituted pyrrolopyrimidines and pyrazolopyrimidines as Bruton's Tyrosine Kinase (BTK) degrading agents 冰洲石生物科技公司 2023-11-10 CN disclosed
US-11530222-B2 Substituted pyrrolopyrimidine and pyrazolopyrimidine as Bruton's tyrosine kinase (BTK) degraders ACCUTAR BIOTECHNOLOGY INC. (US) 2022-12-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11530222-B2 Substituted pyrrolopyrimidine and pyrazolopyrimidine as Bruton's tyrosine kinase (BTK) degraders BTK, LYN, SYK MAP2K1 1816/4885MAP2K2 1006/4885MAPT 4299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.